Partners
Pacific Marine Biotech
Expertise Partner
Pacific Marine Biotech is a biopharmaceutical company pioneering marine-based treatments for Glioblastoma Multiforme (GBM) and DIPG. Founded on the discovery of marine-derived products, we aim to harness the untapped potential of marine organisms to develop innovative therapies. Our flagship product, Immune 12, is advancing towards U.S. FDA approval for clinical trials, while Australian GBM trials are set to launch in late 2024. We are committed to bringing new hope to patients battling these challenging brain tumors.
Renishaw
Exhibition Partner
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuse™ drug delivery system, predictable and translatable therapy infusions in R&D and clinical trials can become a reality. Our Lab2Clinic™ service supports pharma through the R&D journey, translating into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships. All this is underpinned by our FDA-cleared, CE-marked stereotatic products borne out of a +50-year precision engineering heritage.
End Brain Cancer Initiative
Exhibition Partner
The End Brain Cancer Initiative (EBCI), formerly the Chris Elliott Fund, www.EndBrainCancer. org, is a 501 (c)3 non-profit Patient Advocacy organization focused on early drug development and increasing patient and care partner access to advanced treatments, diagnostics, devices, technology, clinical trials, etc. and on advancing and turning science and data into additional FDA approved treatment options for cancer patients, including patients with brain tumors, brain cancer and metastasized disease to the brain and again, increasing patient access through commercialization and reimbursement efforts.
